Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

March 6, 2023

https://www.globenewswire.com/news-release/2023/03/06/2620852/0/en/Annexon-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results-and-Reiterates-Anticipated-Milestones.html

Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023

Oral Small Molecule ANX1502, for Autoimmune Indications, Advances into Multi-Ascending Dose Trial

Read more at globenewswire.com

Related news for (ANNX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.